<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03943550</url>
  </required_header>
  <id_info>
    <org_study_id>WP40161</org_study_id>
    <secondary_id>2017-004599-74</secondary_id>
    <nct_id>NCT03943550</nct_id>
  </id_info>
  <brief_title>Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Patients With Ulcerative Colitis (UC)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase Ib Study to Investigate the Safety, Tolerability, Pharmacokinetics, Preliminary Efficacy, and Pharmacodynamics of Subcutaneously Administered RO7049665 in Participants With Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal aim of this study is to evaluate the safety and tolerability of RO7049665 in&#xD;
      participants with active ulcerative colitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The decision to terminate study WP40161 is based on the lack of robust clinical improvement in&#xD;
    the underlying condition after 8 weeks of treatment with RO7049665.&#xD;
  </why_stopped>
  <start_date type="Actual">May 14, 2019</start_date>
  <completion_date type="Actual">July 22, 2021</completion_date>
  <primary_completion_date type="Actual">July 22, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>From baseline up to Day 99</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of RO7049665</measure>
    <time_frame>From Day 1 to Day 99</time_frame>
    <description>Blood samples will be taken pre-dose and at multiple time points after dose administration. RO7049665 concentration will be analyzed in serum and the time from SC injection to maximum concentration of RO7049665 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration Observed (Cmax) of RO7049665</measure>
    <time_frame>From Day 1 to Day 99</time_frame>
    <description>Blood samples will be taken pre-dose and at multiple time points after dose administration. RO7049665 concentration will be analyzed in serum and the maximum concentration of RO7049665 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from Time 0 to infinity (AUCinf) of RO7049665</measure>
    <time_frame>From Day 1 to Day 99</time_frame>
    <description>Blood samples will be taken pre-dose and at multiple time points after dose administration. RO7049665 concentration will be analyzed in serum. AUC from time of drug administration extrapolated to infinity (AUCinf) will be determined in a plot of RO7049665 serum concentration versus time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from Time 0 to Time tau (AUC0-t) of RO7049665</measure>
    <time_frame>From Day 1 to Day 99</time_frame>
    <description>Blood samples will be taken pre-dose and at multiple time points after dose administration. RO7049665 concentration will be analyzed in serum. AUC from time of drug administration to time tau (AUC0-t), which is defined as the time of last measurable serum concentration, will be determined in a plot of RO7049665 serum concentration versus time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of RO7049665</measure>
    <time_frame>From Day 1 to Day 99</time_frame>
    <description>Blood samples will be taken pre-dose and at multiple time points after dose administration. RO7049665 concentration will be analyzed in serum. Clearance, which is a measure of the rate at which a drug is metabolized or eliminated, will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (V/F) of RO7049665</measure>
    <time_frame>From Day 1 to Day 99</time_frame>
    <description>Blood samples will be taken pre-dose and at multiple time points after dose administration. RO7049665 concentration will be analyzed in serum. Volume of distribution of RO7049665 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of RO7049665</measure>
    <time_frame>From Day 1 to Day 99</time_frame>
    <description>Blood samples will be taken pre-dose and at multiple time points after dose administration. RO7049665 concentration will be analyzed in serum. t1/2 is the time required for the serum concentration of RO7049665 to be reduced to half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Endoscopy Subscore of the Mayo Clinic Score (MCS-ES)</measure>
    <time_frame>Day 29 and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)</measure>
    <time_frame>Day 29 and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Histology Score of Sigmoid Colon Biopsies</measure>
    <time_frame>Day 29 and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Mayo Clinic Score (MCS)</measure>
    <time_frame>Day 29 and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-Drug Antibodies</measure>
    <time_frame>From Day -1 to Day 99</time_frame>
    <description>Anti-drug antibody assays will be used to detect anti-drug antibodies against RO7049665. Samples which are positive for anti-drug antibodies will be further assessed using a neutralizing antibody assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in White Blood Cells</measure>
    <time_frame>Pre-dose and Post-dose from Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>RO7049665</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a subcutaneous (SC) dose of RO7049665 every 2 weeks for 4 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a SC dose of matching placebo every 2 weeks for 4 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7049665</intervention_name>
    <description>Multiple ascending doses of RO7049665 will be administered SC.</description>
    <arm_group_label>RO7049665</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be administered SC.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with Ulcerative Colitis (UC) for at least 12 weeks prior to screening&#xD;
&#xD;
          -  Screening colonoscopy for colorectal cancer conducted within the prior two years if a&#xD;
             history of pancolitis with disease duration ≥ 8 years or history of left-sided colitis&#xD;
             and disease duration ≥12 years&#xD;
&#xD;
          -  Evidence of disease activity at time of screening&#xD;
&#xD;
          -  Insufficient clinical response to standard of care (SOC) therapy or intolerance to SOC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Crohn's disease or indeterminate colitis&#xD;
&#xD;
          -  History of infection with hepatitis B, human immunodeficiency virus (HIV), active&#xD;
             hepatitis C virus (HCV) infection, or other chronic infection&#xD;
&#xD;
          -  Active infections requiring systemic therapy with antibiotic, antiviral or antifungal&#xD;
             or febrile illness within 7 days before Day -1&#xD;
&#xD;
          -  History of primary or acquired immunodeficiency&#xD;
&#xD;
          -  Abnormal hematologic values&#xD;
&#xD;
          -  Abnormal hepatic enzyme or hepatic function values&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Institute of Clinical Medicine</name>
      <address>
        <city>Tbilisi</city>
        <zip>112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Research Centre Gyogyszervizsgalo Kozpontot Kft.</name>
      <address>
        <city>Balatonfüred</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE ÁOK I. sz. Belgyógyászati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARENSIA Phase 1 Unit- Spitalul Clinic Republican Location</name>
      <address>
        <city>Chisinau</city>
        <zip>MD-2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Adonis&quot; LLC</name>
      <address>
        <city>Kapitanovka Village</city>
        <state>KIEV Governorate</state>
        <zip>08112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Moldova, Republic of</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

